The idea was, and that was actually mainly done in Europe because at that time, we were not able really, at least for a lot of patients to get hold of cilta-cel, to compare patients that would potentially qualify for the cilta-cel study, the CARTITUDE-1 study and see how these patients would perform when receiving standard of care therapy.
And looking at this comparison, it was very clear that the CAR-T cell therapy was much more effective and obviously even less toxic than a lot of the other standard of care combinations that were used for the patients in this comparative trial...
The idea was, and that was actually mainly done in Europe because at that time, we were not able really, at least for a lot of patients to get hold of cilta-cel, to compare patients that would potentially qualify for the cilta-cel study, the CARTITUDE-1 study and see how these patients would perform when receiving standard of care therapy.
And looking at this comparison, it was very clear that the CAR-T cell therapy was much more effective and obviously even less toxic than a lot of the other standard of care combinations that were used for the patients in this comparative trial.
So in summary, the BCMA directed CAR-T cell product cilta-cel was clearly superior to any chosen standard of care therapy for patients with advanced relapsed/refractory multiple myeloma.